| Diabetes Mellitus
Admelog vs Fiasp
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Admelog vs Fiasp with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFiasp has a higher rate of injection site reactions vs Admelog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fiasp but not Admelog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Admelog
Fiasp
At A Glance
Subcutaneous, Continuous subcutaneous infusion (pump), Intravenous
Within 15 minutes before or immediately after meals
Rapid-acting insulin analog
SC injection
With meals
Rapid-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Individualize dose based on route of administration, metabolic needs, blood glucose monitoring, and glycemic control goal. Subcutaneous injection: Administer within 15 minutes before or immediately after a meal into abdominal wall, thigh, upper arm, or buttocks. Continuous subcutaneous infusion (insulin pump): Administer via pump in accordance with pump instructions; change reservoir at least every 7 days. Intravenous infusion: Administer only after dilution (0.1-1 unit/mL in 0.9% Sodium Chloride) under medical supervision. Rotate injection/infusion sites to reduce lipodystrophy risk.
Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.
Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.
Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro or any excipient in ADMELOG
- Episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any excipient in FIASP
Adverse Reactions
Most common (>=5%) Nasopharyngitis (13%), upper respiratory tract infection (6%).
Severe hypoglycemia 13.5% in type 1 diabetes (52 weeks), 2.4% in type 2 diabetes (26 weeks).
Postmarketing Medication errors with accidental insulin substitution, localized cutaneous amyloidosis at injection site.
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)
Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain
Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site
Pharmacology
Insulin lispro is a rapid-acting insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake by skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Admelog
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Fiasp
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (9/12) · Qty limit (8/12)
UnitedHealthcare
Admelog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Fiasp
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Admelog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Fiasp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Admelog.
No savings programs available for Fiasp.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdmelogView full Admelog profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.